Miltenyi Biotec B.V. & Co. KG. (4/29/24). "Press Release: Miltenyi Biotec and MiLaboratories Announce Strategic Partnership to Advance Next-generation Therapies". Bergisch Gladbach & San Francisco, CA.

	Organisation	Miltenyi Biotec B.V. & Co. KG
	Group	Miltenyi Biotec (Group)
	Organisation 2	MiLaboratories Inc.
	Product	MiXCR software platform
	Product 2	cell and gene therapy manufacturing (CGT manufacturing)
	Person	Schmitz, Jürgen (Miltenyi Biotec 202404 Managing Director (CSO))
	Person 2	Poslavsky, Stanislav (Stan) (MiLaboratories 202404 CEO + Co-Founder)

Miltenyi Biotec, a global pioneer in biotechnology, and MiLaboratories, a leader in RNA immune technologies are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies. This collaboration combines MiLaboratories' cutting-edge RNA kit technology for immune sequencing with Miltenyi Biotec's robust production and commercialization capabilities.

Under this agreement, MiLaboratories will grant exclusive rights to its innovative RNA kits immune sequencing technology to Miltenyi Biotec. This technology has been instrumental in advancing research and development in the field of immunology and personalized medicine. Miltenyi Biotec will leverage its global reach and expertise in biotechnology to produce and commercialize these kits, making them widely available to researchers and clinicians worldwide.

A cornerstone of this partnership is the integration of MiLaboratories' renowned software solutions, MiXCR and Platforma, into Miltenyi Biotec's offerings. These software platforms are leaders in next-generation sequencing (NGS) data analysis, providing powerful, user-friendly tools for genomic data interpretation. Customers purchasing RNA kits from Miltenyi Biotec will now benefit from seamless access to MiXCR and Platforma, enhancing their research capabilities and efficiency.

Jürgen Schmitz, Managing Director at Miltenyi Biotec, added, "We are thrilled to partner with MiLaboratories, a company that shares our commitment to advancing human health. Their RNA kits technology for immune sequencing complements our molecular analysis product portfolio perfectly. Moreover, their software solutions will offer our customers unparalleled support in data analysis. Together, we are building the future for next-generation therapies."

"This partnership is a significant milestone in our mission to accelerate the development of next-generation therapies," said Stan Poslavsky, CEO of MiLaboratories. "By combining our innovative RNA technologies and software platforms with Miltenyi Biotec's manufacturing and commercial strengths, we are poised to make a substantial impact in the field of genomics and personalized medicine."

This partnership is expected to accelerate the pace of discovery and development in the field of genomics, offering researchers and clinicians new tools to explore the complexities of genetic information and foster the development of innovative therapies.

For more information about this partnership, please contact:
Miltenyi Biotec

Kim Münster, Corporate Communications
E-mail: corpcom@miltenyi.com

About Miltenyi Biotec

Miltenyi Biotec is a global leader empowering biomedical research and advancing cellular therapy. The company's solutions support all stages of cell and gene therapy product development from process and analytical development to commercial-scale manufacturing. With a commitment to excellence and innovation, Miltenyi Biotec is dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

MiLaboratories

Stan Poslavsky, CEO
E-mail: press@milaboratories.com

About MiLaboratories

MiLaboratories is a leading developer of RNA kit technologies and software solutions for NGS data analysis. With a focus on innovation and precision, MiLaboratories' products are at the forefront of genomics research and personalized medicine.

Record changed: 2024-05-08